AKESOgen
Industry: Biomarker profiling
AKESOgen conducts genomic analysis and biomarker profiling for clients in biotech, pharmaceuticals and academic and government research. Using techniques such as DNA isolation, next-generation sequencing, genotyping, expression profiling and methylation profiling, the company provides key data for research scientists.
In an early success for their biomarker profiling technology, AKESOgen’s founders discovered two genes that can predict drug toxicity to Paclitaxel, commonly used in cancer treatment.
The company also provides clinical diagnostic and clinical trial services, with expertise in biobanking assay development.
AKESOgen’s clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society and Kaiser Permanente. In 2015, AKESOgen made Inc. magazine’s list of America’s Fastest-Growing Private Companies, ranked 44th in Healthcare.
Company website: AKESOgen
